10-Q: Novanta Inc. Q1 2026 Revenue Up 10.4%, EPS Declines

Novanta Inc. reported a 10.4% increase in revenue for the first quarter of 2026, reaching $257.7 million, driven by growth in both its segments, though earnings per share saw a decline.

Summary

• Novanta Inc. reported total revenue of $257.7 million for the three months ended April 3, 2026, a 10.4% increase compared to $233.4 million in the same period last year.
• The Automation Enabling Technologies segment revenue grew by 6.6% to $131.2 million, while the Medical Solutions segment revenue increased by 14.8% to $126.5 million, partly due to a recent acquisition.
• Gross profit increased by 9.0% to $113.6 million, but the total gross profit margin slightly decreased to 44.1% from 44.7% year-over-year.
• Operating income decreased by 15.1% to $27.5 million, impacted by higher selling, general, and administrative expenses and increased restructuring, acquisition, and related costs.
• Basic earnings per common share (EPS) were $0.52, down from $0.59 in the prior year period, and diluted EPS were $0.51, down from $0.59.
• The company ended the quarter with $388.8 million in cash and cash equivalents.
• Restructuring, acquisition, and related costs were $2.6 million for the quarter, compared to a net gain of $2.5 million in the prior year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with solid revenue growth indicating demand for Novanta's technologies, but tempered by declining profitability and increased operating expenses.

Positives

• Total revenue increased by 10.4% to $257.7 million, driven by growth in both the Automation Enabling Technologies and Medical Solutions segments.
• The Medical Solutions segment showed strong growth of 14.8%, partly attributed to the recent acquisition of Keonn Technologies.
• Gross profit increased by $9.2 million to $113.6 million.
• Net cash provided by operating activities significantly increased to $51.6 million from $31.7 million in the prior year period.
• The company maintained a strong liquidity position with $388.8 million in cash and cash equivalents and an undrawn revolving credit facility of $850 million.

Negatives

• Operating income decreased by 15.1% to $27.5 million due to increased operating expenses.
• Selling, general and administrative (SG&A) expenses increased by $8.8 million, or 19.3%, to $54.4 million, and as a percentage of revenue.
• Restructuring, acquisition, and related costs were $2.6 million, a significant increase from the prior year's net gain of $2.5 million.
• Both basic and diluted EPS declined compared to the prior year period, with basic EPS at $0.52 and diluted EPS at $0.51.
• Gross profit margin decreased slightly to 44.1% from 44.7%, attributed to higher material, freight, and tariff costs, and regionalized manufacturing strategy costs.

Risks

• Global economic challenges including inflation, supply chain disruptions, and evolving trade policies continue to impact costs and margins.
• Tariffs imposed by the U.S. government and retaliatory measures from other countries have increased costs and contributed to margin compression.
• Geopolitical conflicts have contributed to increased global energy prices, supply chain uncertainty, and rising freight and commodity costs.
• The company's results are subject to cyclical end-market fluctuations, particularly in the advanced industrial market.
• Potential for increased cyberattacks targeting critical infrastructure and technology companies due to geopolitical conflicts.
• Inflationary conditions in materials and components may not be fully offset by price increases, negatively affecting results.
• The company faces extensive medical device regulations that could impede product approval or sales.
• Risks associated with integrating recent and future acquisitions.

Future Outlook

The company expects its future operating cash flows to be sufficient to meet its operating and capital expenditure needs for at least the next 12 months. It also has the ability to expand its borrowing capacity and may seek additional capital through various means for business development activities.

Management Comments

• The company is executing its strategy to drive sustainable, profitable growth through a diversified business model, focusing on increasing medical sales and penetrating high-growth industrial applications.
• Management believes the Purchasing Managers Index (PMI) may provide an indication of the impact of general economic conditions on sales into the advanced industrial end market.
• The company is strengthening its operational performance by deploying lean manufacturing principles and advancing strategic sourcing initiatives.
• Management is focused on advancing a 'people first' culture that promotes a growth mindset and continuous employee development.

Industry Context

StockSavvy.ai notes that Novanta Inc.'s performance reflects broader trends in the medical technology and advanced industrial automation sectors, with increased demand for precision and automation solutions. However, macroeconomic headwinds like inflation and supply chain issues are impacting profitability across the industry.

Comparison to Industry Standards

• Novanta's gross profit margin of 44.1% is competitive within the specialized industrial technology sector, though slightly below its own prior year performance.
• The company's revenue growth of 10.4% outpaces some broader industrial manufacturing indices, indicating strong performance in its niche markets.
• The increase in SG&A expenses as a percentage of revenue (21.1% vs 19.5%) suggests investment in growth initiatives or cost pressures common in the industry.
• Competitors like Cognex Corporation (CGNX) and Rockwell Automation (ROK) also face similar challenges with input costs and supply chain disruptions, but Novanta's diversified end-market exposure provides some resilience.

Legal Proceedings

• The company is subject to various legal proceedings and claims that arise in the ordinary course of business, but does not believe the outcome will have a material adverse effect.

Stakeholder Impact

• Shareholders: Diluted EPS decreased, but the company maintained a strong cash position and authorized further share repurchases.
• Employees: Share-based compensation expense increased, reflecting ongoing equity awards.
• Customers: Revenue growth indicates continued demand for Novanta's products, though increased costs may eventually impact pricing.
• Suppliers: Increased material and freight costs are impacting gross margins.

Next Steps

• The company anticipates substantially completing the 2025 restructuring program by the end of 2026.
• The company expects the UK pension plan buy-in contract to progress to a corresponding buy-out in the second half of 2027.
• The company expects to record an aggregate share-based compensation expense of $64.6 million over a weighted average period of 2.23 years subsequent to April 3, 2026.

Key Dates

Recommendation

While revenue growth is positive, the decline in EPS and increased operating costs, coupled with ongoing macroeconomic uncertainties, warrant a cautious 'hold' stance. Further clarity on margin improvement and successful integration of acquisitions will be key.

Keywords

Novanta Inc., 10-Q, Quarterly Report, Medical Solutions, Automation Enabling Technologies, Revenue Growth, Earnings Per Share, Financial Results, SEC Filing, Keonn Technologies